Regulation of water homeostasis is of vital importance for all terrestrial organisms. In most mammals, including humans, the maintenance of water balance is critically dependent on water intake, the sensation of thirst, and the regulation of water excretion in the kidney, which is under the control of the antidiuretic hormone arginine vasopressin (AVP). 1 In the past decade, our insight into the AVP-mediated renal concentration mechanism has substantially improved with the elucidation of the roles of crucial molecular players in this process. The identification of disease-causing genes in hereditary disorders of water balance has been extremely helpful in identifying these pivotal molecules.
In normal physiology, AVP is secreted into the circulation by the posterior pituitary gland, in response to an increase in serum osmolality or a decrease in effective circulating volume (see diagram). In the kidney, AVP binds to the V2 vasopressin reeptor in the basolateral membranes of collecting-duct cells in the last portion of the nephron (see diagram). Occupancy of this receptor results, by means of signaling through a guanine nucleotide-binding regulatory protein (G protein), in mediated activation of adenylate cylase and the formation of cyclic adenosine monophosphate (cAMP). cAMP, in turn, activates protein kinase A, which promotes the fusion of cytoplasmic vesicles containing aquaporin-2 water-channel proteins with the apical membrane. As a result, this normally water-tight membrane becomes water-permeable. Driven by the osmotic gradient of sodium, water is then transcellularly reabsorbed, entering the cells through aquaporin-2 in the apical membrane and leaving the cells for the interstitium through aquaporin-3 and aquaporin-4, which reside in the basolateral membrane. The withdrawal of AVP results in endocytosis of the water channels, restoring the water-impermeable state of the apical membrane.
Proof of principle for the critical roles of both the V2 receptor and aquaporin-2 in orchestrating the AVP-mediated renal concentration mechanism came from the identification of mutations in the genes encoding these proteins in patients with congenital nephrogenic diabetes insipidus. 2 This rare genetic disorder is characterized by a failure to concentrate urine despite normal or elevated levels of AVP. Polyuria and polydipsia, usually associated with hypernatremia, are typical features of this disorder. The disease is particularly serious in infants, in whom recurrent episodes of dehydration may result in severe neurologic deficits, growth retardation, or even death. Mutations in the gene encod- ing the V2 receptor (AVPR2) cause the X-linked form of congenital nephrogenic diabetes insipidus, and mutations in the gene encoding aquaporin-2 are responsible for both the autosomal recessive and autosomal dominant forms. The V2 receptor is a typical member of the large superfamily of G protein-coupled receptors, which includes receptors for hormones, neurotransmitters, light, odorants, lipids, and ions. Once an agonist binds to such a receptor, an intracellular signal cascade is induced through the coupling and activation of a G protein. G protein-coupled receptors play key roles in almost all physiological functions, and mutations in the genes encoding these receptors have been identified in patients with a variety of inherited and acquired disorders, such as retinitis pigmentosa, hypothyroidism and hyperthyroidism, dwarfism, fertility disorders, obesity, and even cancer. 3 Most such mutations that are associated with disease are inactivating mutations, resulting in reduced or total lack of response to the agonist. These loss-of-function mutations are almost exclusively germ-line mutations.
Activating (gain-of-function) mutations in G protein-coupled receptors, which induce constitutive receptor activation in the absence of the agonist, occur less frequently and consist primarily of somatic mutations that have been identified in certain adenomas and malignant tumors. Such activating mutations with germ-line transmission have been identified in only a few inherited disorders (see  table) .
At present, more than 180 different mutations in AVPR2 have been described. These mutations all cause congenital nephrogenic diabetes insipidus and, consistently, are inactivating mutations, resulting in receptor malfunction at different levels, such as reduced receptor expression at the cell surface or disturbances in hormone binding and G protein coupling.
In this issue of the Journal (pages 1884-1890), Feldman and coauthors describe two unrelated male infants with euvolemic hyponatremia and serum hypo-osmolality, along with inappropriately elevated urine osmolality and urine sodium concentrations. At first glance, the disorder in these boys resembles the syndrome of inappropriate antidiuretic hormone secretion (SIADH), a relatively common disorder characterized by insufficient suppression of AVP secretion in relation to the degree of hypo-osmolality, which leads to inappropriate urine concentration. Since serum AVP levels were undetectably low in both boys, Feldman et al. ruled out SIADH and hypothesized that a hyperactive V2 receptor could be the underlying cause of the disorder. Sequencing of AVPR2 in the two patients revealed a hemizygous point mutation in each. In an in vitro functional assay, both mutations were shown to lead to the production of a constitutively active V2 receptor. The consequence was AVP-independent, and therefore inappropriate, activation of V2 receptor-mediated renal urine concentration. Remarkably, and for reasons that remain unexplained, neither patient showed any clinical or biochemical sign of constitutive activation of extrarenal V2 receptors, which are known to mediate increases in circulating coagulation and fibrinolytic factors and a decrease in diastolic blood pressure after AVP stimulation.
The two identified activating AVPR2 mutations result in substitutions of the same amino acid, located in a part of the receptor protein that is highly conserved among G protein-coupled receptors and that is involved in G protein coupling. Elucidation of the exact mechanism underlying the activation of these mutant V2 receptors will undoubtedly be The syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a common cause of hyponatremia. We describe two infants whose clinical and laboratory evaluations were consistent with the presence of SIADH, yet who had undetectable arginine vasopressin (AVP) levels. We hypothesized that they had gain-of-function mutations in the V2 vasopressin receptor (V2R). DNA sequencing of each patient's V2R gene ( AVPR2 ) identified missense mutations in both, with resultant changes in codon 137 from arginine to cysteine or leucine. These novel mutations cause constitutive activation of the receptor and are the likely cause of the patients' SIADH-like clinical picture, which we have termed "nephrogenic syndrome of inappropriate antidiuresis."
luid homeostasis depends on proper water intake, governed by an intact thirst mechanism, and on urinary excretion of free water, mediated by appropriate secretion of arginine vasopressin (AVP) (also known as antidiuretic hormone). 1 AVP exerts its antidiuretic action by binding to the V2 vasopressin receptor (V2R), a G protein-coupled receptor, on the basolateral membrane of epithelial cells in the collecting duct of the kidney. Ligand binding activates the V2R, stimulating adenylate cyclase by means of G s proteins. The resulting increase in intracellular cyclic AMP (cAMP) promotes shuttling of intracellular vesicles containing the water channel aquaporin-2 to the apical membrane of the collecting-duct cells, thereby increasing water permeability and inducing antidiuresis.
Clinical disorders of water balance are common, and alterations in many steps of this pathway have been described. 1 Urinary concentrating defects associated with diabetes insipidus may result from a deficiency of AVP or from nephrogenic causes, such as X-linked, inactivating mutations in the V2R or autosomal recessive or autosomal dominant lesions in aquaporin-2. 2 Conversely, the syndrome of inappropriate antidiuretic hormone secretion (SIADH) manifests as an inability to excrete a free water load, with inappropriately concentrated urine and resultant hyponatremia, hypo-osmolality, and natriuresis. SIADH occurs in the setting of euvolemia, without evidence of renal disease or thyroxine or cortisol deficiency. Though usually transient, SIADH may be chronic; it is often associated with drug use or a lesion in the central nervous system or lung. When the cardinal features of SIADH were defined by Bartter and Schwartz, 3 AVP levels could not be measured. Subsequently, radioimmunoassays have revealed that SIADH is usually associated with measurably elevated serum levels of AVP. We describe two unrelated male infants whose clinical presentation was consistent with the presence of chronic SIADH but who had undetectable AVP levels. We postulated that novel activating mutations of the V2R might account for their unique presentation. Evaluation revealed novel activating mutations of the V2R leading to what we term "nephrogenic syndrome of inappropriate antidiuresis" (NSIAD).
Patient 1 presented at 3 months of age with irritability, and Patient 2 presented at 2.5 months of age with two generalized seizures. Both children had had unremarkable early neonatal courses. Both were exclusively bottle-fed formula (7 mmol of sodium per liter). Both infants had mild systolic hypertension with otherwise normal physical examinations. Initial laboratory evaluations demonstrated hyponatremia with normal serum levels of potassium and bicarbonate (Table 1) . Both children had serum hypo-osmolality with inappropriately elevated urinary osmolality and urinary sodium levels. Both had low blood urea nitrogen and low or lownormal serum creatinine levels, low or suppressed plasma renin activity, and normal aldosterone levels, indicating euvolemia. Serum cortisol, thyroidfunction tests, and coagulation studies were all normal. Imaging studies of the head and chest were unremarkable, with the exception of a small pars intermedia cyst in Patient 2. Despite clinical and laboratory presentations consistent with the presence of SIADH, serum AVP levels were undetectable in both patients (Quest Diagnostics Nichols Institute). Both children were initially treated with fluid restriction, followed by the administration of an osmotic agent (urea), resulting in increased urinary output and normalization of the serum sodium level.
Neither child had a family history of hyponatremia or of an SIADH-like syndrome. Both patients had no siblings. The mother of Patient 1, subsequently found to be heterozygous for an activating mutation of AVPR2 (see below), had normal simultaneous serum sodium levels (140 mmol per liter) and serum and urine osmolality (293 and 795 mOsm per kilogram of water, respectively).
The parents of the patients provided written informed consent for the publication of the case reports through a protocol approved by the institutional review board of the University of California at San Francisco.
mutation analysis
Genomic DNA from the two patients and their mothers was isolated from whole blood with the use of the Puregene Blood Kit (Gentra Systems). The entire coding region of the V2R gene, AVPR2, was amplified as described previously. 4 The resulting amplicons were sequenced with multiple forward and reverse primers with the use of Big Dye (version 3.1) sequencing chemistry and an ABI Prism sequencer (model 3100, Applied Biosystems) according to the manufacturer's protocols. SeqScape software (Applied Biosystems) was used to assemble the sequence data and compare the results with the AVPR2 reference sequence (GenBank accession number NT 025965).
construction of vasopressin expression constructs pCDNA3 (Invitrogen) was used as the control plasmid. Human wild-type V2R complementary DNA (cDNA), 5 subcloned into pCDNA3, was used as a normal control and template for mutagenesis. Sitedirected mutagenesis was performed with the use of a QuickChange II site-directed mutagenesis kit (Stratagene). Mutations were confirmed by direct sequencing. Genomic DNA was isolated from both boys and their mothers, and the V2R gene, AVPR2, was sequenced directly. AVPR2 is X-linked, and therefore, paternal DNA is not informative. Each patient carried a mutation in codon 137 of AVPR2. In Patient 1, nucleotide 770 was mutated from cytosine to thymine, changing arginine to cysteine at codon 137 (R137C); in Patient 2, nucleotide 771 was mutated from guanine to thymine, changing arginine to leucine at codon 137 (R137L) (Fig. 1A) . Arginine 137 maps to the predicted second cytoplasmic loop, near the cytoplasmic boundary of the third transmembrane domain; this same amino acid is mutated to histidine (R137H) in a form of familial nephrogenic diabetes insipidus (Fig. 1B) . The mother of Patient 1 was heterozygous for the R137C mutation, whereas the mother of Patient 2 was homozygous for wild-type AVPR2, suggesting that Patient 2 had a spontaneous mutation.
To evaluate the effect of these novel mutations on V2R function, we developed a functional assay for V2R. Production of cAMP has previously been used to assess many G protein-coupled receptors, including V2R 9 ; we adopted our previous procedures 8 to use with V2R. COS-7 cells transiently transfected with the vector alone, wild-type V2R, or the R137H nephrogenic diabetes insipidus mutant induced low levels of cAMP (Fig. 2) . However, basal levels of cAMP production in cells expressing V2R with the R137C mutation were four times the levels in cells expressing wild-type V2R (P=0.01), and cells expressing the R137L mutant had 7.5 times the level of activity of cells expressing wildtype V2R (P<0.004) (Fig. 2) . These results indicate that these novel mutations create a constitutively active V2R and provide an explanation for the hyponatremia with increased urinary osmolality in our patients. The condition in both patients is clinically similar to SIADH, despite the fact that AVP levels were undetectable. G protein-coupled receptors constitute the largest gene family of receptors involved in signal transduction and are responsible for regulating many physiological processes. 10 Many diseases are caused by mutations in G protein-coupled receptors. 11, 12 For some G protein-coupled receptors, a particular disease state has been ascribed to inactivating mutations that render the receptors unresponsive to ligand, whereas a converse condition has been linked to gain-of-function mutations, resulting in constitutive activation.
Although many different inactivating mutations of the X-linked V2R have been described that cause nephrogenic diabetes insipidus, 2 to our knowledge, no naturally occurring activating mutations of the V2R have been reported previously. The two cases described here are characterized by chronic SIADH but with undetectable AVP levels, constituting a novel example of gain-of-function mutations caused by a hemizygous V2R mutation. In the light of these findings, we suggest referring to all SIADH-like conditions as syndromes of inappropriate antidiuresis (SIAD) and that these two case reports constitute a subtype, NSIAD. To our knowledge, these cases are the only reported examples in which mutations affecting the same amino acid cause two different genetic diseases: R137H causes nephrogenic diabetes insipidus, and R137L and R137C cause NSIAD (Fig. 1B) .
The mechanism by which these missense mutations constitutively activate the V2R requires further investigation. V2R, a class 1b G protein-coupled receptor, 12, 13 exists in the plasma membrane in equilibrium with inactive and active conformations. 10 The binding of ligand shifts the equilibrium to the active state, permitting coupling with intracellular G proteins and activation of intracellular effectors. With activation, V2R is desensitized through phosphorylation by specific G protein-coupled receptor kinases. Subsequent recruitment of b arrestin to the phosphorylated receptor terminates the signal by blocking further interaction with G proteins and also initiates receptor internalization through its ability to bind clathrin and other endocytic adapters. 14 By comparison with other class 1 G proteincoupled receptors, the highly conserved motif of aspartic acid, arginine, and tyrosine or histidine (DRY/H) in V2R at the junction of the third transmembrane domain and second intracellular loop P<0.004
appears to be critical for receptor function. The arginine residue in the DRY/H motif appears to be invariant, though the aspartic acid and tyrosine may be replaced by other amino acids without altering the function (e.g., from aspartic acid to glutamic acid). 15 The arginine residue in the DRY/H motif corresponds to R137, the site of the inactivating R137H mutation in nephrogenic diabetes insipidus and the activating R137C and R137L mutations in NSIAD. The R137H mutant behaves as a constitutively desensitized receptor, since it is phosphorylated, binds to b arrestin (thereby blocking its ability to activate G proteins), and is sequestered in intracellular vesicles. 16 Constitutively activated mutant G protein-coupled receptors have also been created by altering this DRY/H motif 17 -for example, through in vitro mutation of aspartate to alanine at codon 136 in the V2R. 18 The NSIAD mutations found in this domain may stabilize the receptor in an active conformation, activating G proteins and downstream signaling events in the absence of ligand. In theory, such a gain of function could also affect many other aspects of V2R biology, including phosphorylation, internalization, down-regulation, and recycling to the cell membrane.
The effects of the constitutive activation of V2R may not be limited to the kidney. V2R is also expressed in endothelial cells, where it appears to mediate vasodilation after the administration of the vasopressin analogue desmopressin 19, 20 and to mediate the rise in circulating levels of von Willebrand factor and tissue plasminogen activator. 21 We thought that these responses, which are absent in patients with nephrogenic diabetes insipidus, 22 might be constitutively activated in our patients with NSIAD. However, we found no clinical or laboratory evidence of coagulopathy in either patient ( Table 1) .
The frequency of NSIAD is not known, but it may not be rare. Previous studies of patients with SIADH have noted variable patterns of AVP secretion, particularly in response to water loading and water restriction. 23 As many as 10 to 20 percent of affected patients have AVP levels at or below the limits of detection by radioimmunoassay. Thus, some of these patients may in fact have NSIAD due to V2R-activating mutations. Such patients would probably have clinical presentations similar to those in our patients, although the severity and clinical course may depend on the nature of the mutation.
Patients with NSIAD would be expected to have low AVP levels. However, since the AVP assay is not optimized to identify low values, we recommend sequencing the V2R gene to identify specific mutations before the diagnosis of NSIAD is finalized. Other patients may be identified who have the NSIAD phenotype but without V2R mutations, suggesting the presence of additional defects in this signaling cascade. One such possibility would be an activating mutation in aquaporin-2.
Treatment of NSIAD poses a challenge. Water restriction improved serum sodium levels and osmolality in both infants but limited calorie intake in these formula-fed infants. Agents that act downstream from the V2R, such as demeclocycline or lithium, might antagonize the constitutively activated receptors, but they have potentially limiting adverse effects. AVP antagonists are under clinical development but would probably be ineffective, given the ligand-independent nature of the lesion. 24 Ideally, one might be able to use an inverse agonist that would suppress receptor activity in the absence of agonist; two potential nonpeptide V2R inverse agonists have been studied in vitro. 18 In the absence of a definitive therapy, we have successfully treated our patients with urea to induce an osmotic diuresis. 25 This approach has occasionally been used for the treatment of chronic SIADH in adults. 26 Study of the V2R has been important for understanding the physiology of water balance and has served as a prototype for G protein-coupled receptor biology. Further characterization of NSIAD may offer additional insights into fluid homeostasis and clinical disease, as well as expand our understanding of G protein-coupled receptor signaling.
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